BioLineRx Ltd. (NASDAQ:BLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

A number of other research analysts have also issued reports on BLRX. Roth Capital set a $3.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Wednesday, August 9th. Maxim Group set a $3.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Tuesday, August 8th. HC Wainwright set a $4.00 target price on BioLineRx and gave the stock a “buy” rating in a report on Saturday, June 3rd. ValuEngine lowered BioLineRx from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Finally, Oppenheimer Holdings, Inc. assumed coverage on BioLineRx in a report on Friday, August 4th. They set an “outperform” rating and a $3.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $2.59.

Shares of BioLineRx (BLRX) traded down 0.94% during midday trading on Thursday, reaching $1.05. 953,836 shares of the company were exchanged. BioLineRx has a 52-week low of $0.80 and a 52-week high of $1.42. The company’s market capitalization is $100.40 million. The firm’s 50 day moving average is $1.06 and its 200-day moving average is $0.97.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, equities analysts forecast that BioLineRx will post ($0.24) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/07/biolinerx-ltd-blrx-upgraded-to-hold-at-zacks-investment-research-2.html.

Institutional investors and hedge funds have recently modified their holdings of the stock. Sabby Management LLC purchased a new position in BioLineRx in the 1st quarter worth about $3,018,000. KCG Holdings Inc. increased its stake in BioLineRx by 715.9% in the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 153,687 shares in the last quarter. Citadel Advisors LLC increased its stake in BioLineRx by 443.4% in the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 86,481 shares in the last quarter. Benchmark Capital Advisors increased its stake in BioLineRx by 227.3% in the 1st quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in BioLineRx in the 1st quarter worth about $126,000. 32.27% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.